covid-19 treatments

COVID-19 treatments

Previous Next

Quality medications help save lives: Reducing the risks from substandard and falsified COVID-19 treatments

The supply and demand imbalances caused by the COVID-19 pandemic has created a surge in substandard and falsified treatments. USP is working with public health organizations, pharmacopeias, manufacturers and regulators in the U.S. and around the world to combat poor-quality medicines and build the public’s trust in COVID-19 treatments. Our resources and tools help ensure the quality of medical products for drug ingredients and finished products. USP is committed to strengthening the supply of trusted, quality medicines needed to fight the pandemic.

substandard and falsified medicines whitepaper
Protecting the supply chain of COVID-19 health products

USP responds to the surge of substandard and falsified health products triggered by the COVID-19 pandemic.

Read the white paper

remdesivir toolkit
USP Methods to Assist in Detecting Falsified Remdesivir

Newly released methods to identify substandard and falsified remdesivir can help ensure hospitalized COVID-19 patients are receiving the quality treatments they need.

See the resource

dexamethasone
GPHF-Minilab™ Screening Tool for dexamethasone

A Concise Quality Control Guide on Essential Drugs and other Medicines: COVID-19 Special Issue

Access the screening tools

Favipiravir tablets
IMWP Monographs on Favipiravir and on Favipiravir tablets

Pharmacopoeias are working together to support the global public health response to the pandemic. The recently developed IMWP monographs can help manufacturers, regulators and stakeholders fight substandard or falsified Favipiravir, an important antiviral treatment for COVID-19.

Comment on the monographs

Amphotericin B
Amphotericin Standards for COVID-19 associated Mucormycosis Concern in India

As of 15th July, India has reported over 45,432 cases and 4,252 deaths due to mucormycosis. The mucormycosis, now termed COVID-19 associated mucormycosis (CAM), has been declared an epidemic and a notifiable disease in India as infections rise among COVID-19 patients.

Read more

interferon
Interferon Beta-1A reference standard now available

As researchers around the world investigate COVID-19 Interferon Beta-1A therapies, a new USP Reference Standard can help them ensure purity and reliability of their work.

Read more